Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 1 (2016), Article ID 1:IJCPP-110, 6 pages
https://doi.org/10.15344/2456-3501/2016/110
Research Article
Population Pharmacokinetic Analysis of Oral Tacrolimus in Patients with Glomerulonephritis

MiKyong Kim Shim1,2, Jong Mann Kim3, Kyoung Eob Choi1, Myeong Gyu Kim2, Nayoung Han2, Eunhee Ji4 and JungMi Oh2*

1College of Pharmacy& Institute of Pharmaceutical Sciences, CHA University, Pocheon, Republic of Korea
2Research Institute of Pharmaceutical Sciences,College of Pharmacy, Seoul National University, Seoul, Republic of Korea
3Health Insurance Review and Assessment Service, Republic of Korea
4College of Pharmacy & Research Institute of Pharmaceutical Sciences, Gachon University, Incheon, Republic of Korea
Dr. Jung Mi Oh, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea; E-mail: jmoh@snu.ac.kr
31 March 2016; 02 June 2016; 04 June 2016
Shim KM, Kim JM, Choi KE, Kim MG, Han N, et al. (2016) Population Pharmacokinetic Analysis of Oral Tacrolimus in Patients with Glomerulonephritis. Int J Clin Pharmacol Pharmacother 1: 110. doi: https://doi.org/10.15344/2456-3501/2016/110
© 2016 Shim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Foundation NK (2013) Glomerulonephritis [View]
  2. Chadban SJ, Atkins RC (2005) Glomerulonephritis. Lancet 365: 1797- 1806 [CrossRef] [PubMed]
  3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. (2005) Kidney disease as a risk factor for development of cardiovascular disease a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 108: 2154-2169 [CrossRef] [Google Scholar] [PubMed]
  4. Korean Society of Nephrology RC (2005) Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry 2005 -The Korean Society of Nephrology. 25: S425-S57
  5. System USRD (2015) USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD2015
  6. Chae DW (2013) Current Status of Primary Glomerulonephritis. Korean J Med 84: 1-5 [CrossRef] [Google Scholar]
  7. Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int 82: 840-856 [CrossRef] [Google Scholar] [PubMed]
  8. Group KW (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 186-197
  9. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa (2007) Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 71: 924-930 [CrossRef] [Google Scholar] [PubMed]
  10. Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, et al. (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 31: 187-197 [CrossRef] [Google Scholar] [PubMed]
  11. Han N, Yun HY, Hong JY, Kim IW, Ji E, et al. (2013) Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Euro J Clin Pharmacol 69: 53-63 [CrossRef] [Google Scholar] [PubMed]
  12. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC (2001) Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 28: 753-758 [CrossRef] [Google Scholar] [PubMed]
  13. Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65: 757-773 [CrossRef] [Google Scholar] [PubMed]
  14. Joy MS, Frye RF, Nolin TD, Roberts BV, La MK, et al. (2014) In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy 34: 114-122 [CrossRef] [Google Scholar] [PubMed]
  15. Venkataramanan R, Jain A, Warty V, Abu-Elmagd K, Furakawa H, et al. (1991) Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc 23: 931-933 [Google Scholar] [PubMed]
  16. Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL (1975) Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 55: 1182-1189 [CrossRef] [Google Scholar] [PubMed]
  17. Keller F, Maiga M, Neumayer HH, Lode H, Distler A (1984) Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 9: 275-282 [CrossRef] [Google Scholar] [PubMed]
  18. Sam WJ, Joy MS (2010) Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit 32: 594-605 [CrossRef] [Google Scholar] [PubMed]
  19. Xiaoli D, Qiang F (2009) Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome. J Clin Pharmacol 49: 782-788 [CrossRef] [Google Scholar] [PubMed]
  20. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev19: CD003961 [CrossRef] [Google Scholar] [PubMed]
  21. Martins L, Ventura A, Branco A, Carvalho MJ, Henriques AC, et al. (2004) Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? Transplant Proc 36: 877-879 [CrossRef] [Google Scholar] [PubMed]
  22. Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41: 813-851 [CrossRef] [Google Scholar] [PubMed]
  23. Jusko W, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, et al. (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57: 281-290 [CrossRef] [Google Scholar] [PubMed]
  24. Han N, Yun HY, Hong JY, Kim IW, Ji E, et al. (2013) Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 69: 53-63 [CrossRef] [Google Scholar] [PubMed]
  25. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC (2001) Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 28: 753-758 [CrossRef] [Google Scholar] [PubMed]
  26. Golubović B, Vučićević K, Radivojević D, Kovačević SV, Prostran M, et al. (2014) Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. Eur J Pharm Sci 52: 34-40 [CrossRef] [Google Scholar] [PubMed]
  27. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S (2007) Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 64: 750-757 [CrossRef] [Google Scholar] [PubMed]
  28. Antignac M, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, et al. (2005) Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 61: 409- 16 [CrossRef] [Google Scholar] [PubMed]
  29. Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57: 479-484 [CrossRef] [Google Scholar] [PubMed]
  30. Li D, Lu W, Zhu JY, Gao J, Lou YQ, et al. (2007) Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 32: 505-515 [CrossRef] [Google Scholar] [PubMed]
  31. Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, et al. (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet 45: 59-75 [CrossRef] [Google Scholar] [PubMed]
  32. Staatz CE, Willis C, Taylor PJ, Tett SE (2002) Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72: 660-669 [CrossRef] [Google Scholar] [PubMed]
  33. Administration USFaD. Prograf® capsule label information
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.